The robotic central pancreatectomy with end-to-end anastomosis is feasible and safe for tumor in the pancreatic neck and proximal portion of pancreatic body. The operative techniques of this operation are presented.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
* These authors contributed equally
The robotic central pancreatectomy with end-to-end anastomosis is feasible and safe for tumor in the pancreatic neck and proximal portion of pancreatic body. The operative techniques of this operation are presented.
Central pancreatectomy is carried out for the treatment of benign or low-malignant potential tumors located in the pancreatic neck or proximal part of pancreatic body. With technological development, the robotic surgical system has shown its advantage in minimally invasive surgery and been increasingly applied in central pancreatectomy. However, reconstruction of the continuity of pancreas with end-to-end anastomosis after robotic central pancreatectomy has not been applied. In this study, we report surgical techniques for robotic central pancreatectomy with end-to-end anastomosis. The pancreas is reconstructed by duct-to-duct anastomosis of the pancreatic duct with a pancreatic stent inserted in the two stumps of pancreatic duct, and by end-to-end anastomosis of the pancreatic parenchyma. Compared with traditional central pancreatectomy with pancreaticoenteric anastomosis, this approach decreases the operative injury to the patient, and also conserves the integrity and continuity of the digestive duct and pancreatic duct. The robotic surgical system integrated with multiple instruments with flexible and precise movement is particularly suitable for the dissection and reconstruction of the pancreatic duct. We found that robotic central pancreatectomy with end-to-end anastomosis is safe and feasible, and we need more experience to evaluate its best indications and long-term outcomes.
Central pancreatectomy is increasingly performed for the treatment of benign or low-malignant potential tumors located in the pancreatic neck or proximal part of pancreatic body1. Compared with the pancreaticoduodenectomy or distal pancreatectomy, central pancreatectomy resects less tissues and conserves more pancreatic parenchyma and function. Currently, the major approaches for the pancreas reconstruction are over-sewing the cephalic pancreatic stump and performing a pancreaticojejunostomy or pancreaticogastrostomy to the distal stump2,3. These two approaches are widely used in the op....
Access restricted. Please log in or start a trial to view this content.
Written informed consent was obtained from the patient for the publication of this report and any accompanying videos and images.
1. Preoperative Preparation
Access restricted. Please log in or start a trial to view this content.
The operation process was smooth. The operative time was 141 mins and the intraoperative blood loss was about 50 mL. The size of the resected pancreas was about 5.5 × 2.5 × 2.5 cm (Figure 4). The patient recovered smoothly after surgery and discharged on the 6th postoperative day. When the patient was discharged, he had a normal diet and normal defecation, and had no fever, no abdominal pain or distension. The routine blood examination and blood bi.......
Access restricted. Please log in or start a trial to view this content.
Malignant tumors located in the pancreas neck and the proximal part of the pancreatic body are often treated with pancreaticoduodenectomy or distal pancreatectomy. However, for benign or low malignant potential tumors in those sites, the standard pancreaticoduodenectomy or distal pancreatectomy will remove excessive normal tissues and result in excessive injury. Therefore, the central pancreatectomy or pancreatic enucleation, known as "parenchyma-sparing pancreatectomy", becomes a preferable choice for the treatm.......
Access restricted. Please log in or start a trial to view this content.
No competing financial interests exist.
The authors have no acknowledgments.
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| da Vinci Robotic Surgical System | Intuitive Surgical, USA | Si | |
| EndoWrist Permanent Cautery Hook | Intuitive Surgical, USA | 420183 | |
| Harmonic Ace Curved Shears | Ethicon, USA | 420275 | |
| EndoWrist Large needle Driver | Intuitive Surgical, USA | 420006 | |
| EndoWrist Cadiere Forceps | Intuitive Surgical, USA | 420049 | |
| EndoWrist Black Diamond Micro Forceps | Intuitive Surgical, USA | 420033 | |
| Lapro-Clip 8 mm Absorbable Clips | Covidien , USA | 8886848882 | |
| 5-0 non-absorbable suture | Ethicon, USA | M8717 | |
| 4-0 non-absorbable suture | Ethicon, USA | D9775 | |
| 5-0 absorbable suture | Ethicon, USA | D9943 | |
| Absorbable hemostas | Ethicon, USA | W1912 | |
| Laparoscopic Ultrasound Probe | BK Ultrasound, Denmark | 8666-RF | transducer contact surface: 30*5mm; Frequence: 4.3-10 MHz |
| Pancreatic stent | Yaxin Medical, Suzhou, China | 1.2 mm | |
| Antibiotics (ceftriaxone sodium for injection) | Roche, Shanghai, China | H10983036 | ceftriaxone sodium (2g) adding to normal saline (100ml), once per day. |
| Proton pump inhibitors (lansoprazole injection) | Luoxin Pharmaceutical, Linyi, China | H20055118 | lansoprazole injection (30 mg) adding to normal saline (100ml), twice per day. |
| Somatostatin (Somatostatin for injection) | Merck Serono, Germany | H20090929 | Somatostatin for injection (6000ug) adding to nornal saline to a total of 48ml, 2 ml/h |
| Analgesic | |||
| Analgesic (sufentanil Citrate injection) | Humanwell Healthcare, Fuzhou, China | H20054171 | sufentanil Citrate (200ug), Ondansetron hyrochloride (20mg), adding to normal saline to a total of 80 ml, 1 ml/h |
| Analgesic (Ondansetron hyrochloride injection) | Qilu Pharmaceutical, Hainan, China | H10970065 | sufentanil Citrate (200ug), Ondansetron hyrochloride (20mg), adding to normal saline to a total of 80 ml, 2 ml/h |
| Parenteral nutrition | |||
| Parenteral nutrition(Compond vitamin injection) | Pude Pharmaceutical, Datong, China | H20093720 | 1 piece |
| Parenteral nutrition(Compond amino acid injection) | Kelun Pharmaceutical, Chengdu, China | H20066058 | 500 ml |
| Parenteral nutritionz(Fat emulsion injection) | Fresenius Kabi AB, Sweden | H20160019 | 250 ml |
| Parenteral nutrition(10%KCl injection) | Jinyao Pharmaceutical, Tianjin, China | H12020518 | 50 ml |
| Parenteral nutrition(10%NaCl injection) | CR, Double-Crane, Beijing, China | H11020865 | 50 ml |
| Parenteral nutrition(Insulin injection) | No.1 biochemical and pharmaceutical, Shanghai, China | H31020519 | 28 Unit |
Access restricted. Please log in or start a trial to view this content.